SCHEMBL1042234

SCHEMBL1042234

CCNC(=O)NC1CCCC(Nc2cc(-c3c[nH]c4ncccc34)cc(Cl)n2)C1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 20/20 0.66
GSK3B P49841 11/20 0.66
PRKACA P17612 13/20 0.63
HIPK2 Q9H2X6 12/20 0.63
DYRK1A Q13627 11/20 0.63
CDK2 P24941 11/20 0.63
MAP4K4 O95819 10/20 0.63
PIM1 P11309 10/20 0.63
ROCK2 O75116 10/20 0.63
CLK2 P49760 9/20 0.63
CDK5 Q00535 9/20 0.63
DAPK3 O43293 9/20 0.63
PRKX P51817 9/20 0.63
PKN2 Q16513 9/20 0.63
MINK1 Q8N4C8 9/20 0.63
MAP4K5 Q9Y4K4 9/20 0.63
STK17A Q9UEE5 9/20 0.63
CDK9 P50750 9/20 0.63
CSNK1A1 P48729 8/20 0.63
PAK4 O96013 8/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1045790 0.94 CDC7 (0.64) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL15190224 0.91 CDC7 (0.65) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL1042707 0.91 CDC7 (0.75) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL1046188 0.90 CDC7 (0.60) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL1045806 0.90 CDC7 (0.68) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL1044224 0.89 CDC7 (0.67) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL1042930 0.89 CDC7 (0.73) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL1044767 0.87 CDC7 (0.70) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL1041679 0.87 CDC7 (0.63) CDC7GSK3BPRKACAHIPK2DYRK1A
SCHEMBL14905755 0.86 CDC7 (0.75) CDC7GSK3BPRKACAHIPK2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP claimed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US claimed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP claimed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO claimed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US claimed
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP disclosed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885GSK3B 442/4885PRKACA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.